SELLAS Life Sciences (SLS) Equity Average (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Equity Average for 9 consecutive years, with $9.4 million as the latest value for Q3 2024.
- Quarterly Equity Average rose 1750.89% to $9.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Sep 2024, up 1750.89% year-over-year, with the annual reading at -$1.6 million for FY2023, 112.4% down from the prior year.
- Equity Average for Q3 2024 was $9.4 million at SELLAS Life Sciences, up from $6.3 million in the prior quarter.
- The five-year high for Equity Average was $31.1 million in Q2 2021, with the low at -$5.9 million in Q4 2023.
- Average Equity Average over 5 years is $12.0 million, with a median of $9.0 million recorded in 2023.
- The sharpest move saw Equity Average crashed 167.65% in 2023, then surged 1750.89% in 2024.
- Over 5 years, Equity Average stood at $18.0 million in 2020, then surged by 30.76% to $23.5 million in 2021, then crashed by 62.84% to $8.7 million in 2022, then plummeted by 167.65% to -$5.9 million in 2023, then skyrocketed by 259.32% to $9.4 million in 2024.
- According to Business Quant data, Equity Average over the past three periods came in at $9.4 million, $6.3 million, and $854000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.